Lexeo Therapeutics, Inc. LXEO
Lexeo Therapeutics, Inc. (Nasdaq: LXEO) is a cardio-renal-metabolic drug developer. Its lead program, LX2006 (AAVrh10 frataxin gene therapy), is in Phase 2 for Friedreich ataxia cardiomyopathy. Its next catalyst on record is Mantle / acquired FA programs: Program prioritization update for acquired FA programs expected in early 2027. (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Mantle / acquired FA programs — Program prioritization update for acquired FA programs expected in early 2027. (2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LX2006 (SUNRISE-FA Phase 1/2; SUNRISE-FA 2 pivotal study; Cornell investigator-initiated trial) | Friedreich ataxia cardiomyopathy | gene therapy | Phase 2 |
| LX2020 (AAVrh10 PKP2 gene therapy), HEROIC-PKP2 Phase 1/2 | PKP2 arrhythmogenic cardiomyopathy | gene therapy | Phase 1 |
| LX2021 (connexin 43 gene therapy) | Desmoplakin cardiomyopathy / dilated cardiomyopathy | gene therapy | Pre-clinical |
Recent results and decisions
- Sep 22, 2026positive Acquired oral program LX3010: approximately six-point mFARS improvement at 16 weeks and mean nine-fold frataxin increase in muscle biopsies across 11 FA patients.
Approximately six-point improvement in mFARS scores at 16 weeks Mean nine-fold increase in frataxin protein levels from baseline in muscle biopsies across 11 FA patients
Filing - Aug 12, 2026started SUNRISE-FA 2 pivotal study initiated in June 2026 with first site activated and first patient enrolled.
The study was initiated in June with activation of the first trial site and enrollment of the first patient.
Filing - Jun 15, 2026positive Open-label cohort (n=16) showed 2.3 points/year slower mFARS progression vs propensity-matched natural history controls (n=45), 95% CI 0.82-3.84, p=0.003 (data as of Dec 2025).
New evidence of neurological functional improvement compared to propensity matched control, with annualized difference in progression of 2.3 points per year (95% CI: 0.82-3.84)
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.